heart failure diagnosis can induce false-negative results in cardiac natriuretic peptides [1, 2]. This is why the cut-off fraction (preserved ejection fraction) and lower levels of particularities, including a frequently normal ejection category is that of obese patients. These have certain markers [1]. Among heart failure patients, a special BNP or NT-proBNP concentrations are heart failure severity than that of BNP (120 min vs. 20 min) [2]. Increased serum as the kidney, the half-life of NT-proBNP is much longer of both occurs in high blood flow-dependent organs such but only the latter is biologically active. Although clearance is cleaved by proteolytic enzymes into NT-proBNP and BNP , proBNP by removal of 26 amino acids. Subsequently, this BNP is pre-proBNP , which is rapidly transformed into result of an increase in parietal stress under volume or by the myocardium directly into systemic circulation as a amino-terminal pro-brain natriuretic peptide) are secreted guiding treatment of heart failure have been described. In addition to these classical, routinely used biomarkers recommended by current guidelines for the diagnosis and treatment of heart failure [1], other biomarkers with a role in stratifying risk or improving at the same time the diagnosis of patients with upper limit values of BNP , as well as obese patients [1, 3]. The cut-off value of this cardiac peptide recommended by current European heart failure guidelines to exclude heart failure is 120 pmol/L [1]. However, it should not be forgotten that tissue damage in heart failure induces a significant inflammatory response with the release of pro-inflammatory cytokines and an increase in the number of cell adhesion molecules [4]. Another important biomarker of inflammatory response in heart failure is galectin-3 (Gal-3), a lectin member of the galectin family [2]. Gal-3 expression is increased in activated macrophages, as well as the heart through proteins and other molecules. Gal-3 plays an important role in pathological cardiac remodeling, particularly by stimulating fibroblast proliferation and collagen deposition. Gal-3 concentrations are increased in patients with heart failure, including those with preserved ejection fraction. This is why Gal-3 may have a role in risk stratification: Gal-3 values >17.8 ng/mL are associated with low risk, Gal-3 values between 17.9 and 25.9 ng/mL show moderate risk, and obesity patients. In this context, identifying other more sensitive biomarkers might contribute to an increase in diagnostic sensitivity and more precise guiding of treatment in this category of patients.

MR-proANP is a promising biomarker for the correct diagnosis of heart failure, much more stable than NT-proANP, which has demonstrated its non-inferiority to BNP in clinical practice, in the diagnosis of acute heart failure, improving at the same time the diagnosis of patients with upper limit values of BNP, as well as obese patients [1, 3]. The cut-off value of this cardiac peptide recommended by current European heart failure guidelines to exclude heart failure is 120 pmol/L [1].

Keywords: heart failure, biomarkers, obesity, atrial fibrillation

Since natriuretic peptides (BNP and NT-proBNP) gained approval for clinical use as biomarkers of heart failure in 2000, they have become extremely useful in making diagnosis, assessing severity, risk of acute events, and guiding therapy of heart failure. In addition to these classical, routinely used biomarkers recommended by current guidelines for the diagnosis and treatment of heart failure [1], other biomarkers with a role in stratifying risk or guiding treatment of heart failure have been described.

BNP (B-type natriuretic peptide) and NT-proBNP (amino-terminus pro-brain natriuretic peptide) are secreted by the myocardium directly into systemic circulation as a result of an increase in parietal stress under volume or pressure overload conditions [1, 2]. The initial product of BNP is pre-proBNP, which is rapidly transformed into proBNP by removal of 26 amino acids. Subsequently, this is cleaved by proteolytic enzymes into NT-proBNP and BNP, but only the latter is biologically active. Although clearance of both occurs in high blood flow-dependent organs such as the kidney, the half-life of NT-proBNP is much longer than that of BNP (120 min vs. 20 min) [2]. Increased serum BNP or NT-proBNP concentrations are heart failure severity markers [1]. Among heart failure patients, a special category is that of obese patients. These have certain particularities, including a frequently normal ejection fraction (preserved ejection fraction) and lower levels of cardiac natriuretic peptides [1, 2]. This is why the cut-off values recommended by natriuretic peptide guidelines for heart failure diagnosis can induce false-negative results in obese patients. In this context, identifying other more sensitive biomarkers might contribute to an increase in diagnostic sensitivity and more precise guiding of treatment in this category of patients.

MR-proANP is a promising biomarker for the correct diagnosis of heart failure, much more stable than NT-proANP, which has demonstrated its non-inferiority to BNP in clinical practice, in the diagnosis of acute heart failure, improving at the same time the diagnosis of patients with upper limit values of BNP, as well as obese patients [1, 3]. The cut-off value of this cardiac peptide recommended by current European heart failure guidelines to exclude heart failure is 120 pmol/L [1].

However, it should not be forgotten that tissue damage in heart failure induces a significant inflammatory response with the release of pro-inflammatory cytokines and an increase in the number of cell adhesion molecules [4]. Another important biomarker of inflammatory response in heart failure is galectin-3 (Gal-3), a lectin member of the galectin family [2]. Gal-3 expression is increased in activated macrophages, as well as the heart through proteins and other molecules. Gal-3 plays an important role in pathological cardiac remodeling, particularly by stimulating fibroblast proliferation and collagen deposition. Gal-3 concentrations are increased in patients with heart failure, including those with preserved ejection fraction. This is why Gal-3 may have a role in risk stratification: Gal-3 values >17.8 ng/mL are associated with low risk, Gal-3 values between 17.9 and 25.9 ng/mL show moderate risk.
and values higher than 25.9 ng/mL indicate high risk [2]. However, so far it is not known whether these values should be adjusted depending on comorbidities. There are also data showing the implication of Gal-3 in the development of obesity, as a modulator of adipogenesis. It seems that Gal-3 concentrations are higher in obese patients, but the links between galectin-3, obesity and heart failure with preserved ejection fraction are still incompletely understood [5].

Also, it is well-known that obese patients have excessive secretion of leptin, an adipokine with pro-inflammatory and atherogenic properties produced by adipocytes [6].

Many obese patients are diagnosed with cardiac arrhythmia, especially atrial fibrillation, which worsens their prognosis, while obese patients with heart failure generally have a more favorable prognosis compared to normal weight or cachectic patients [7, 8].

Determining a greater number of biomarkers in obese patients with heart failure can provide new data, useful for a more accurate characterization and stratification of risk.

In this context, the present study aimed to assess the role that the biomarkers described above can play in overweight and obese patients diagnosed with heart failure, depending on the presence or absence of atrial fibrillation. We also aimed to evaluate possible correlations between leptin levels and these biomarkers of heart failure (NT-proBNP, Gal-3, MR-proANP).

Experimental part
Subjects
The study included 88 overweight and obese patients, admitted to the Cardiology service of the Clinical Rehabilitation Hospital, for cardiac decompensation events. Based on anthropometric measurements, the body mass index (BMI) was calculated. Patients with a body mass index (BMI) ≥ 25 kg/m² were included and 52.2% of them had atrial fibrillation. Heart failure was defined according to the guidelines for the diagnosis and treatment of acute and chronic heart failure, published by the European Society of Cardiology in 2016 [1]. Demographic, clinical, laboratory data and echocardiographic parameters were analyzed. Overweight and obese patients with heart failure were assigned to 2 groups depending on the presence or absence of atrial fibrillation (patients with paroxysmal, persistent or permanent atrial fibrillation were included).

Evaluation of heart failure specific biomarkers
Dosage of NT-proBNP was performed on the day of admission and its measurement was carried out using the chemiluminescence method. The cut-off value for NT-proBNP was 125 pg/mL. MR-proANP, galectin-3 and leptin were used during the ELISA method. For the determination of serum concentrations of MR-proANP, Gal-3 and leptin serum was separated by centrifugation at 1500 g for 10 min at a temperature of 4°C, then was transferred to 1 mL cryotubes and stored at a temperature of -70°C for subsequent analysis.

For the quantitative determination of human mid-regional pro-ANP (MR-proANP) we used a quantitative sandwich enzyme immunoassay technique. Microplates were pre-coated with an antibody specific for MR-proANP. During the test standards and samples are pipetted into the wells and any MR-proANP present is bound by the immobilized antibody. After removing any unbound substances, a biotin conjugated antibody specific for MR-proANP is added to the wells. After washing avidin conjugated Horseradish Peroxidase (HRP) is added. Following a wash step a substrate solution is added and color develops in proportion to the amount of antigen bound in the initial step. The color development is stopped and the intensity of the color measured. Detection range was 39 – 2500 pmol/L.

The ELISA test for the galectin-3 determination is based on a standard sandwich enzyme-linked immuno-sorbent assay method. A monoclonal antibody from mouse specific for Galectin-3 has been precoated onto 96 well plates. Standards and test samples are added to the wells, a biotinylated detection polyclonal antibody from goat specific for Galectin-3 is added subsequently. An incubation period is followed by washing with PBS buffer. Avidin - Biotin-Peroxidase Complex is added and unbound conjugates were washed away with PBS buffer. HRP substrate TMB is used to visualize the enzymatic reaction producing a blue color product. After adding the stop solution the color is changing to yellow. The intensity of this is proportional to the human Galectin-3 amount of the samples. Detection range: 10 - 100 ng/mL.

The leptin serum level was detected also by a sandwich enzyme immunoassay. Standards, controls and samples are incubated in microplate wells pre-coated with polyclonal anti-human leptin antibody. After incubation and washing an HRP-conjugated anti-human leptin antibody is added to the wells and incubated with captured leptin. Following another washing step, the remaining HRP conjugate is allowed to react with the substrate solution (TMB). The reaction is stopped by addition of acidic solution and absorbance of the resulting yellow product is measured. The absorbance is proportional to the concentration of leptin. Detection cut-off value was 0.2 ng/mL. The cut-off values for MR-proANP and Gal-3 were 120 pmol/L and 17.8 ng/mL, respectively.

Statistical analysis
Statistical data was obtained using the SPSS Statistics for Windows software program (version 23, IBM Corporation, Armonk, NY, USA). For continuous variables, mean values including standard deviations and median values were calculated (depending on the normality of distribution). Categorical variables are presented as numbers and percentages. Comparisons between groups were made using the ANOVA test – the Kruskal-Wallis test (for numerical data), or the Chi-square test (for non-numerical data). Pearson and Spearman coefficients were used to describe the relationships between data. Multivariate analysis (for the evaluation of independent predictive factors for NT-proBNP, MR-proANP and galectin-3) was performed taking into consideration age, sex, diabetes mellitus, arterial hypertension, left ventricular ejection fraction, atrial fibrillation, creatinine clearance, body mass index, Charlson comorbidity score. A value of $P <0.05$ was defined as statistically significant.

The patients included in the study were informed about the study protocol and gave their informed consent. The study protocol was approved by the local Ethics Committee and it was conducted in accordance with the WMA International Code of Medical Ethics (Declaration of Helsinki) for experiments involving humans.

Results and discussions
The baseline characteristics of the patients are summarized in table 1. As it can be seen, there are no significant differences except for dilated cardiomyopathy and other arrhythmias, more frequently found in patients with atrial fibrillation. Also, HDL cholesterol was lower in those patients. No
Statistically significant differences were observed between the values of the studied serum biomarkers. Overall, the values of natriuretic peptides NT-proBNP and MR-proANP were significantly increased. The mean value of NT-proBNP was 2410 ± 2676 pg/mL, with a median value of NT-proBNP of 1342 pg/mL. The mean value of MR-proANP was 590 ± 840 pmol/L, and its median value was 246 pmol/L.

The mean value of galectin-3 was 41 ± 41 ng/mL, while its median value was 34 ng/mL. Of the patients included in the study, 66 (75%) had increased Gal-3 values (>17.8 ng/mL).

Of the studied biomarkers, only NT-proBNP was significantly influenced by renal function; there was an inversely proportional relationship between NT-proBNP values and creatinine clearance (r=-0.35, p=0.01). Gal-3 and MR-proANP were not influenced by the alteration of renal function (r=0.07, p=0.4; r=-0.02, p=0.8, respectively).

MR-proANP and galectin-3 values did not significantly vary depending on BMI (p=0.8, p=0.5, respectively).

No statistically significant correlation was found between heart failure-specific biomarkers and leptin secretion in overweight and obese patients with heart failure. Figure 1 presents the relationship between leptin and NT-proBNP: Spearman R correlation = -0.101, p=0.35, and after logarithmic transformation Pearson R = -0.098, p=0.365.

Table 2 shows that this correlation is also not significant depending on the presence or absence of atrial fibrillation. The next figure (fig. 2), illustrates the relationship between MR-proANP and leptin.

As shown in table 3, this correlation is also not significant depending on the presence or absence of atrial fibrillation. Figure 3 illustrates the relationship between galectin-3 and leptin, and table 4 shows the relationship between leptinemia and galectin-3 levels in patients with and without atrial fibrillation.

Determining the serum biomarkers of heart failure, along with clinical data and objective examination, allows a higher diagnostic accuracy for this disorder. Natriuretic peptides are the best known and studied markers of heart failure; there is current convincing evidence that they improve diagnostic performance in heart failure, including in patients with subclinical cardiac dysfunction [1]. They are particularly useful in differentiating cardiac dyspnea from non-cardiac dyspnea [1]. According to ESC guidelines...
for the diagnosis and treatment of heart failure, detection of BNP values lower than 100 pg/mL, NT-proBNP values lower than 125 pg/mL and MR-proANP values lower than 120 pmol/L excludes the diagnosis of heart failure [1]. However, the positive predictive value of these markers is reduced [1]. In order to improve this positive predictive value, The American Heart Association has recently proposed different NT-proBNP cut-off values depending on age: 450 pg/mL for patients aged <50 years, 900 pg/mL for those aged between 50 and 75 years, and 1800 pg/mL for patients aged >75 years, as well as a BNP value >400 pg/mL [2]. Natriuretic peptides remain the gold standard of heart failure biomarkers. ANP and BNP are produced in the atria and ventricles, respectively, in response to volume or pressure overload in heart failure. The biological functions of ANP and BNP include different compensatory mechanisms, such as stimulation of natriuresis, diuresis, vasodilation. Also, in addition to their diagnostic role, they have an extremely important prognostic role; studies have demonstrated a linear relationship between their serum concentrations and cardiovascular mortality [2]. Doust et al. showed that an increase in BNP values by 100 pg/mL is associated with a 35% higher relative risk of death [8]. However, there are some important limitations that should be taken into account when interpreting natriuretic peptide values. Obese patients with heart failure frequently have lower values of cardiac natriuretic peptides [1, 2]; an inverse linear relationship between BMI and natriuretic peptide values was described, as we also demonstrated in previous studies [2, 9, 10]. Regarding atrial fibrillation, NT-proBNP values are increased in patients with this comorbidity, proving potentially useful in stratifying risk.

**Table 2**

| ECG                  | Spearman R (raw data) | p  | Pearson R (log-transformed data) | p  |
|----------------------|-----------------------|----|---------------------------------|----|
| All                  | -0.101                | 0.25| -0.028                          | 0.265|
| AF                   | -0.16                 | 0.287| -0.15                           | 0.287|
| Sinus rhythm         | -0.017                | 0.817| -0.033                          | 0.817|

**Table 3**

| Patient group        | Spearman R (coefficient) | p  | Pearson R (after log-transformic transformation) | p  |
|----------------------|--------------------------|----|---------------------------------|----|
| With AF              | -0.002                   | 0.927| 0.005                           | 0.922|
| Sinus rhythm         | -0.03                    | 0.848| -0.03                           | 0.848|
defining prognosis and even making therapeutic decision [1, 11]. Nevertheless, NT-proBNP values decrease in the presence of obesity in patients with atrial fibrillation [12]. In the current study, NT-proBNP is the only biomarker that showed a statistically significant inverse relationship with left ventricular ejection fraction. Therefore, although NT-proBNP has significantly lower values in obese patients with heart failure compared to the general population, it maintains its prognostic value. However, unlike the other studied biomarkers, only NT-proBNP concentrations were strongly influenced by the presence of renal dysfunction.

ANP prohormone, composed of 126 amino acids, known as proANP, has a longer half-life than that of ANP, its serum measurement being more reliable. In this context, MR-proANP is a promising new biomarker of heart failure, which has proven its non-inferiority to BNP in clinical practice in the diagnosis of acute heart failure, improving at the same time the diagnosis of patients with BNP values in the gray area (between 100 and 500 pg/mL) and obese patients [3]. Determining NT-proBNP and MR-proANP increases diagnostic accuracy among these patients. In the current study, the median value of MR-proANP was 246 pmol/L, significantly increased compared to the cut-off value of 120 pmol/L proposed by current guidelines [1]. Unlike NT-proBNP, this was not correlated with BMI in the studied group of overweight and obese patients. Studies have demonstrated that patients with atrial fibrillation have increased values of MR-proANP, its determination also being useful in identifying persons at high risk for developing atrial fibrillation [13]. The current study did not find higher NT-proBNP or MR-proANP values in overweight or obese patients with heart failure and AF compared to values recorded in heart failure patients with sinus rhythm; these results are similar to those of the BACH trial [14]. Obese patients most frequently develop heart failure with preserved ejection fraction. The new biomarkers of heart failure (cardiac troponins, MR-pro-adrenomedullin, cystatin C, interleukin-6, galectin-3, ST2) are extremely important for improving diagnostic accuracy, explaining the pathophysiological mechanisms involved, as well as for developing new therapies [2]. Galectin-3 is a 30 kDa protein that contains a carbohydrate binding domain of 130 amino acids allowing specific beta-galactosidase binding, and is strongly influenced by the presence of renal dysfunction.

Table 4

|            | Spearman R | p   | Pearson R (after logarithmic transformation) | p   |
|------------|------------|-----|---------------------------------------------|-----|
| All patients | 0.027      | 0.035 | -0.003                                      | 0.977 |
| AF         | 0.032      | 0.13 | 0.032                                       | 0.73  |
| Sinus rhythm | 0.022    | 0.089 | 0.022                                       | 0.889 |

The relationship between leptin and galectin-3 depending on the presence of atrial fibrillation.

Conclusions

In the current study we demonstrated that there is no statistically significant direct relationship between serum leptin concentrations and the levels of the studied HF markers (NT-proBNP, MR-proANP, Gal-3). So, the role of leptin as an independent predictor of heart failure prognosis in overweight and obese patients remains questionable. Certainly, when interpreting the results of this study, the reduced number of patients and the presence of other comorbidities that might have influenced the results should be taken into account. In conclusion, obese patients with heart failure had significantly increased values of all the studied parameters (NT-proBNP, MR-proANP, Gal-3, leptin), but the presence of atrial fibrillation did not influence their levels. At the same time, high leptin levels were not directly correlated with the levels of heart failure-specific biomarkers.
3. YANCY, C.W., JESSUP, M., BOZKURT, B., BUTLER, J., CASEY DE, J.R., COLVIN, M.M., et al. J Card Fail., 8, 2017, p.628-651.
4. RUSTAMOVA, Y., DOBREANU, D. Revista Românã de Medicinã de Laborator, 26, 2018, p.267-270.
5. GARG, A., VIRMANI, D., AGRAWAL, S., AGARWAL, C., SHARMA, A., STEFANINI, G., KOSTIS, J.B. Cardiology., 136, nr. 3, 2017, p.192-203.
6. WANNAMETHEE, S.G., SHAPER, A.G., WHINCUP, P.H., LENNON, L., SATTTAR, N. J Am Coll Cardiol., 58, nr. 18, 2011, p.1870-1877.
7. FONAROW, G.C., CLARK, A.L. Prog Cardiovasc Dis., 61, nr. 2, 2018, p.151-156.
8. DOUST, J.A, PIETRZAK, E., DOBSON, A., GLASZIOU, P. BMJ., 330, nr. 7942, 2005, p.625.
9. DADARLAT, A., SITAR-TAUT, A.V, ZDRENGHEA, D., POP, D., BUZOIANU A. Balneo Research Journal., 9, nr. 1, 2018, p.28-33.
10. AURSULESEI, V., MANA, A., AL NAMAT, R., HUGIANU, M., MOLOCE, A.M., AURSULESEI V., C., CONSTANTIN, M. REV.CHIM.(Bucharest), 69, no. 7, 2018, p.1673-1677
11. RICHARDS, M., DI SOMMA, S., MUELLER, C., NOWAK, R., PEACOCK, W.F., PONIKOWSKI, P. et al. JACC Heart Fail., 1, nr. 3, 2013, p.192-199.
12. ZHENG, L.H., WU, L.M., YAO, Y., CHEN, W.S., BAO, J.R., HUANG, W., et al. PLoS One., 9, nr. 8, 2014, p.e105249.
13. BERNTSSON, J., SMITH, J.G., NILSSON, P.M., HEDBLAD, B., MELANDER, O., ENGSTROM, G. Eur J Prev Cardiol., 24, nr. 8, 2017, p.788-795.
14. MAISEL, A., MUELLER, C., NOWAK, R., PEACOCK, W.F, LANDSBERG, J.W, PONIKOWSKI, P., et al. J Am Coll Cardiol., 55, 2010, p.2062-2076.
15. DE BOER, R.A., EDELMANN, F., COHEN-SOLAL, A., MAMAS, M.A., MAISEL, A., PIESKE, B. Eur J Heart Fail., 15, nr. 10, 2013, p.1095-1101.
16. GEHLKEN, C., SUTHAHAR, N., MEIJERS, W.C., DE BOER, RA. Heart Fail Clin., 14, nr. 1, 2018, p.75-92.
17. FRENCH, B., WANG, L., KY, B., et al. J Card Fail., 22, nr. 4, 2016, p.256-262.
18. VAN DER VELDE, A.R., GULLESTAD, L., UELAND, T., et al. Circ Heart Fail., 6, nr. 2, 2013, p.219-226.
19. MENINI, S., IACOBINI, C., BLASETTI FANTAUZZI, C., PESCE, C.M., PUGLIESE, G. 2016, article ID 9618092.
20. FARCA, A.D., RUSU, A., STOIA, M. A., VIDA-SIMITI, L., A. Cytokine, 103, 2018, p.46-49
21. MOCAN HOGNOGI, L.D., MOCAN HOGNOGI, R.F., RUSU, A., STOIA, M., VIDA-SIMITI, L. Rev. Chim.(Bucharest), 2017, 68, no. 9, p.2108-2111.
22. SZABO, T., SCHERBAKOV, N., MOCAN HOGNOGI, R.F., MALUTAN, A., FARCAS, A.D. VIDA-SIMITI, L. Nutr Metab Cardiovasc Dis., 24, nr. 1, 2014, p.50-56.

Manuscript received: 20.02.2019